Cleave Gains Further Validation From Investors With Addition Of $10M To Its Series A
This article was originally published in The Pink Sheet Daily
Executive Summary
The California biotech proves that an early-stage company can be just as attractive to investors as a proof-of-concept biotech if the science is strong.